Open AccessMutational profile of ZBTB16‐RARA‐positive acute myeloid leukemia
Author(s) -
Fabiani Emiliano,
Cicconi Laura,
Nardozza Anna Maria,
Cristiano Antonio,
Rossi Marianna,
Ottone Tiziana,
Falconi Giulia,
Divona Mariadomenica,
Testi Anna Maria,
Annibali Ombretta,
Castelli Roberto,
Lazarevic Vladimir,
Rego Eduardo,
Montesinos Pau,
Esteve Jordi,
Venditti Adriano,
Della Porta Matteo,
Arcese William,
LoCoco Francesco,
Voso Maria Teresa
Publication year - 2021
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.3904
Subject(s) - biology , myeloid leukemia , acute promyelocytic leukemia , cancer research , arid1a , myeloid , chromosomal translocation , retinoic acid , mutation , gene , genetics
Background The ZBTB16‐RARA fusion gene, resulting from the reciprocal translocation between ZBTB16 on chromosome 11 and RARA genes on chromosome 17 [t(11;17)(q23;q21)], is rarely observed in acute myeloid leukemia (AML), and accounts for about 1% of retinoic acid receptor‐α ( RARA) rearrangements. AML with this rare translocation shows unusual bone marrow (BM) morphology, with intermediate aspects between acute promyelocytic leukemia (APL) and AML with maturation. Patients may have a high incidence of disseminated intravascular coagulation at diagnosis, are poorly responsive to all‐ trans retinoic acid (ATRA) and arsenic tryoxyde, and are reported to have an overall poor prognosis. Aims The mutational profile of ZBTB16‐RARA rearranged AML has not been described so far. Materials and methods We performed targeted next‐generation sequencing of 24 myeloid genes in BM diagnostic samples from seven ZBTB16‐RARA + AML , 103 non‐RARA rearranged AML, and 46 APL. The seven ZBTB16‐RARA ‐positive patients were then screened for additional mutations using whole exome sequencing ( n = 3) or an extended cancer panel including 409 genes ( n = 4). Results ZBTB16‐RARA +AML showed an intermediate number of mutations per patient and involvement of different genes, as compared to APL and other AMLs. In particular, we found a high incidence of ARID1A mutations in ZBTB16‐RARA +AML (five of seven cases, 71%). Mutations in ARID2 and SMARCA4 , other tumor suppressor genes also belonging to SWI/SNF chromatin remodeling complexes, were also identified in one case (14%). Discussion and conclusion Our data suggest the association of mutations of the ARID1A gene and of the other members of the SWI/SNF chromatin remodeling complexes with ZBTB16‐RARA +AMLs, where they may support the peculiar disease phenotype.